November 16, 2014

Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes

.   .   

In this 6-year follow-up study of patients enrolled in ADVANCE, there was no evidence that intensive glucose control during the trial led to long-term benefits with respect to mortality or macrovascular events. Though event rates were small, there was a reduction in end-stage renal disease in those patients in the intensive glucose arm, hazard ratio 0.54; 95% CI, 0.34 to 0.85; P=0.007.

Related Articles:

Chronic Kidney Disease, Diabetes